Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.
Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

Afimkibart, an Anti-TL1A Antibody, in Moderately-to-Severely Active Ulcerative Colitis: Insights from the Phase 2b TUSCANY-2 Trial

The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite primary endpoint statistical thresholds not being met by total Mayo scores.
Evaluating the Role of Estrogen Replacement Therapy Combined with Resistance Exercise in Older Women with Knee Osteoarthritis: Insights from a Randomised Clinical Trial

Evaluating the Role of Estrogen Replacement Therapy Combined with Resistance Exercise in Older Women with Knee Osteoarthritis: Insights from a Randomised Clinical Trial

This trial assessed the additive effects of low-dose transdermal estrogen replacement therapy combined with resistance exercise in women aged 65+ with knee osteoarthritis, finding no overall significant benefit but suggesting potential improvements in early-stage disease and mental health.
Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especially in postmenopausal women.